Previous close | 3.5700 |
Open | 3.6300 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 3.3900 - 3.8700 |
52-week range | 2.5300 - 20.5000 |
Volume | |
Avg. volume | 28,354 |
Market cap | 8.536M |
Beta (5Y monthly) | 0.99 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthcare ConferenceDate: Thursday, June 6, 2024Time: 12:30 PM EDTLocation: New York, NY The presentation will be webcast live and available for replay under “Events & Presentations” in the Investors section of the C
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Event: TD Cowen’s 5th Annual Oncology Innovation SummitDate: Tuesday, May 28, 2024Time: 8:30 AM EDTLocation: Virtual The presentation will be webcast live and available for replay under “Events & Presentations” in the Inve
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, May 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2024 and provided an update on its broad